Showing results (161-170 of 177) with videos related to
Sort By:
Pageof 18
Journal of Immunology (Baltimore, Md. : 1950)|January 22, 2002
Selective decrease in circulating V alpha 24+V beta 11+ NKT cells during HIV type 1 infectionHans J J van der Vliet, B Mary E von Blomberg, Mette D Hazenberg, et al.Clinical Immunology (Orlando, Fla.)|January 11, 2005
Circulating Valpha24+Vbeta11+ NKT cell numbers and dendritic cell CD1d expression in hepatitis C virus infected patientsHans J J van der Vliet, Johan W Molling, B Mary E von Blomberg, et al.Journal of Immunology (Baltimore, Md. : 1950)|July 21, 2007
Identification and characterization of ErbB-3-binding protein-1 as a target for immunotherapySaskia J A M Santegoets, Marco W J Schreurs, Anneke W Reurs, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 29, 2010
Selective transduction of dendritic cells in human lymph nodes and superior induction of high-avidity melanoma-reactive cytotoxic T cells by a CD40-targeted adenovirusBasav N Hangalapura, Dinja Oosterhoff, Shikhar Aggarwal, et al.Journal of Immunology (Baltimore, Md. : 1950)|October 23, 2002
Prolonged maturation and enhanced transduction of dendritic cells migrated from human skin explants after in situ delivery of CD40-targeted adenoviral vectorsTanja D de Gruijl, Sylvia A Luykx-de Bakker, Bryan W Tillman, et al.Human Molecular Genetics|May 13, 2005
Disruption of Abcc6 in the mouse: novel insight in the pathogenesis of pseudoxanthoma elasticumTheo G M F Gorgels, Xiaofeng Hu, George L Scheffer, et al.Blood|June 21, 2008
Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 proteinRuud Oerlemans, Niels E Franke, Yehuda G Assaraf, et al.Journal for Immunotherapy of Cancer|March 19, 2021
T cell infiltration on local CpG-B delivery in early-stage melanoma is predominantly related to CLEC9A<sup>+</sup>CD141<sup>+</sup> cDC1 and CD14<sup>+</sup> antigen-presenting cell recruitmentBas D Koster, Marta López González, Mari Fcm van den Hout, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2017
Local Adjuvant Treatment with Low-Dose CpG-B Offers Durable Protection against Disease Recurrence in Clinical Stage I-II Melanoma: Data from Two Randomized Phase II TrialsBas D Koster, Mari F C M van den Hout, Berbel J R Sluijter, et al.Experimental Hematology & Oncology|January 12, 2013
Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitorsSue Ellen Verbrugge, Marjon Al, Yehuda G Assaraf, et al.Pageof 18